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Exosomes-secreted microRNAs play an important role in metastatic spread. During this process breast
cancer cells acquire the ability to transmigrate through blood vessels by inducing changes in the
endothelial barrier. We focused on miR-939 that is predicted to target VE-cadherin, a component of
adherens junction involved in vessel permeability. By in silico analysis miR-939 was found highly
expressed in the basal-like tumor subtypes and in our cohort of 63 triple-negative breast cancers (TNBCs)
its expression signiﬁcantly interacted with lymph node status in predicting disease-free survival prob-
ability. We demonstrated, in vitro, that miR-939 directly targets VE-cadherin leading to an increase in
HUVECs monolayer permeability. MDA-MB-231 cells transfected with a miR-939 mimic, released miR-
939 in exosomes that, once internalized in endothelial cells, favored trans-endothelial migration of
MDA-MB-231-GFP cells by the disruption of the endothelial barrier. Notably, when up taken in endo-
thelial cells exosomes caused VE-cadherin down-regulation speciﬁcally through miR-939 as we
demonstrated by inhibiting miR-939 expression in exosomes-releasing TNBC cells.
Together, our data indentify an extracellular pro-tumorigenic role for tumor-derived, exosome-asso-
ciated miR-939 that can explain its association with worse prognosis in TNBCs.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Metastasis is the leading cause of mortality in cancer patients. In
Europe, 10e20% of breast cancer (BC) patients relapse and develop
distant metastatic disease after treatment [1,2]. The aggressiveness
of metastatic BC underscores the need to elucidate the molecular
mechanisms underlying the metastatic process in order to develop
efﬁcient treatment.
microRNAs (miRNAs) are small (19e22 nucleotides) non-coding
RNAs able to suppress the translation of targetmRNAs by binding to
their 30UTR and are critical regulators of cellular processes such as
proliferation, differentiation, development and death, especially in
cancer [3]. miRNAs can play a crucial role in modulating the tumort (E. Tagliabue).
er Ireland Ltd. This is an open accemicroenvironment by their internalization in exosomes and
transfer to neighboring cells [4,5]. Exosomes are 30- to 100-nm
membrane vesicles released by most cell types, and cancer pa-
tients are characterized by a higher number of blood circulating
exosomes compared with healthy individuals [6,7]. The role of
exosomes in mediating intercellular communication by interacting
with recipient cells is well-established [8]: cancer cells release
exosomes to transfer protein, soluble factors, RNAs and miRNAs to
modulate the microenvironment [9e11] and alter vessel perme-
ability [4]. Traversing the endothelial barrier is a crucial step in the
metastatic process; indeed, this barrier regulates not only the
passage of ﬂuid and nutrients through the vascular wall, but also
the transmigration of cells, such as leukocytes and tumor cells [12].
The loss of membrane-associated adhesion molecules such as
cadherin 5 (CDH5, VE-cadherin) and zonula occludens 1 (ZO-1) on
endothelial cells has been shown to favor the migration of invasive
cancer cells [4,13,14].ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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extracellular communication, we focused on miR-939, which is
reported to be upmodulated in lung adenocarcinomas [15], hepa-
tocellular carcinomas [16] and ovarian cancer tissues [17], and
associated with prognosis in esophageal squamous cell carcinomas
[18]. However, the precise function of miR-939 in breast cancer
remains unclear. Here, we investigated the role of exosome-
associated miR-939 in promoting blood vessel invasion by BC cells.Materials and methods
Patient samples
RNA was extracted using the miRNeasy FFPE kit (Qiagen, Valencia, CA), from
FFPE specimens of 63 TNBC patients diagnosed between 2002 and 2006 in our
Institute (Fondazione IRCCS Istituto Nazionale dei Tumori) based on immunohis-
tochemical criteria (<1% cell positivity for estrogen receptor, progesterone receptor
and HER2 expression classiﬁed as 0 or 1þ). All patients gave written consent to use
of their FFPE specimens for future investigations and research purposes. All data
were analyzed anonymously and all experiments were in compliance with the
Helsinki Declaration. miR-939 was evaluated by qRT-PCR using the median value as
cut-off to separate tumors into miR-939-positive and -negative groups.Cell lines, transfection and actinomycin D treatment
All human BC cell lines and human embryonic kidney line HEK-293, purchased
from ATCC (Rockville, MD, USA) were authenticated using the short tandem repeat
proﬁling method in our Institute facility. For further information see Supplemental
material and methods.
Primary human umbilical vascular endothelial cells (HUVECs) were harvested
from the vein of human umbilical cords [19] and cultured for a maximum of 10
passages in MCDB131 medium supplemented with 20% FBS, 100 mg/ml ECGS
(endothelial cell growth factor supplement, Sigma Aldrich, St. Louis, MO, USA),
100 mg/ml heparin (Sigma Aldrich), 1% penicillin/streptomycin and 1% L-glutamine
on ﬂasks pre-coated with 1% gelatin (Sigma Aldrich).
Cells were transfected with 100 or 50 nM of hsa-miR-939-5p mimic (miR-939)
(Ambion®, Thermo Fisher Scientiﬁc) or miRCURY LNA™microRNA inhibitor for hsa-
miR-939-5p (LNA-939i) (Exiqon A/S, Vedbeak, Denmark), respectively, using
RNAimax (Invitrogen, Waltham, MA, USA) according to the manufacturer's
instructions.
To determine VE-cadherin mRNA stability, transfected HUVECs were treated
with 1 mg/ml actinomycin D for 4, 8 and 24 h.In silico analysis, plasmid construction and luciferase assay
To identify miR-939 targets, in silico analysis in the miRWalk 2.0 database was
performed using DIANAmt, miRanda, miRDB, miRwalk and TargetScan 7.1 prediction
tools.
A 986-bp region of the VE-cadherin (CDH5) 30 untranslated region (30UTR)
including wild type or mutated hsa-miR-939-5p binding sites was cloned in the
pmiR-GLO dual-luciferase miRNA target expression vector (Promega, Waltham, MA,
USA) and a luciferase assay was performed.
A miR-939-5p Luciferase Reporter Vector (pmiR939-Reporter) (Signosis, Santa
Clara, CA, USA) was used as reporter of miR-939 expression in cells. See
Supplementary material and methods for detailed protocols.Proliferation, migration and invasion assays
Detailed protocols can be found in Supplementary material and methods.Isolation of exosomes and labeling
Exosomes were puriﬁed from 2.5e3  106 BC cells cultured for 48 and 72 h in
medium supplemented with 10% exosome-depleted FBS prepared as previously
described [20]. Exosomes were isolated using ExoQuick-TC exosome precipitation
solution (System Biosciences, Mountain View, CA, USA) as described [5]. Exosomes
obtained were dissolved in 60 ml of MCDB131, examined for protein concentration
using the Bradford protein assay, and labeled with the green lipophilic ﬂuorescent
dye PKH67 (Sigma Aldrich) according to the manufacturer's instructions.Fig. 1. miR-939 is expressed in human breast carcinomas. A, miR-939 expression in
human breast carcinomas and normal mammary tissues in The Cancer Genome Atlas
(TCGA) database. B, miR-939 expression in human breast carcinomas according to
PAM50 classiﬁcation. **P < 0.01, ***P < 0.001 by unpaired Student's t-test.Tube formation, permeability and trans-endothelial migration assay
Tube formation assay was performed as described [21]. Permeability was
assessed based on the passage of rhodamine B isothiocyanate-dextran (average MW
70,000; Sigma Aldrich) through HUVECs monolayer grown on 0.4-mm pore size
ﬁlters (BD Bioscience) as reported [4]. Trans-endothelial invasion assay was per-
formed as described [4]. See Supplementary material and methods.Western blot and immunoﬂuorescence analyses
The following antibodies were used for western blot analysis: polyclonal anti-
human CD144 (VE-cadherin) (Cell Signaling, Danvers, MA, USA), 1:1000; anti-
human CD63, clone H5C6 (Abcam, Cambridge, UK), 0.5 mg/mL, and anti-tubulin
clone DM1A (Sigma Aldrich), 0.2 mg/mL. For the immunoﬂuorescence analysis a
polyclonal anti-human CD144 (VE-cadherin) (BMS158, eBioscience, San Diego, CA,
USA), 6 mg/mL, was used. See Supplementary material and methods for detailed
protocols.
RNA extraction and qRT-PCR analysis
RNAwas extracted using QIAzol lysis reagent (Qiagen, Valencia, CA) according to
manufacturer's instruction and quantiﬁed using the NanoDrop ND-100 spectro-
photometer (NanoDrop Technologies). For exosomes, a spike-in ath-miR-159a was
added to QIAzol at a ﬁnal concentration of 4 nM and used as internal control.
miRNAs expressionwas analyzed using the Taqman microRNA reverse transcription
kit and Taqman microRNA assay kit (Applied Biosystems, Foster City, CA, USA) ac-
cording to the manufacturer's instructions. Gene expression was analyzed using
High Capacity RNA-to-cDNA kit (Applied Biosystems) and speciﬁc primers
(Supplementary Table SI) for hsa-pri-miR-939 and CDH5. Detailed protocols in
Supplementary material and methods.
Statistical analyses
Association between two categorical variables was tested by Fisher's exact test.
Differences between means of independent groups were tested using unpaired
Student's t-test.
An approach based onminimal-depth variable importance estimated by random
survival forests [22] was used to select prognostic factors for disease-free survival
(DFS). Adjusted hazard ratios (HRs) of prognostic factors together with 95% conﬁ-
dence intervals (CIs) were estimated by ﬁtting multivariable Cox survival models.
Synergy Index S was estimated as proposed in [23] equation (7). S > 1 indicated the
presence of a synergistic interaction between two variables. Differences were
considered signiﬁcant at P  0.05. Analyses were carried out using GraphPadPrism
v5 (GraphPad software) and R 3.2.3 computing packages.
Results
miR-939 is expressed at higher levels in TNBC and associated with
worse DFS
Analysis of the public available dataset The Cancer Genome Atlas
(TCGA) showed a signiﬁcantly higher expression of miR-939 in
human BCs compared to normal mammary tissues (Fig. 1A).
Furthermore, analysis of miR-939 expression levels in BC subtypes
divided according to PAM50 classiﬁcation [24] showed a signiﬁcant
upmodulation of miR-939 in the highly aggressive basal-like tumor
subgroup (Fig. 1B).
In our cohort of 63 TNBCs miR-939 expression revealed no as-
sociation with clinicopathological variables (Supplementary
Table SII). Permutation accuracy variable importance estimated
by random survival forests [22] identiﬁed miR-939 expression as a
prognostic factor for DFS, together with nodal involvement (N),
multifocality and size (Supplementary Fig. S1A). Multivariate Cox
survival analysis using the above prognostic covariates revealed a
Table 2
List of miRNAs targeting CDH5-30UTR.
Gene miRNA Number of sites Site type Context þþ scorea
CDH5 hsa-miR-939-5p 3 8mer 0,25
CDH5 hsa-miR-762 3 8mer 0,24
CDH5 hsa-miR-1343-5p 3 8mer 0,23
CDH5 hsa-miR-1913 4 7mer-m8 0,2
CDH5 hsa-miR-1254 3 7mer-a1 0,2
CDH5 hsa-miR-324-3p 4 7mer-m8 0,19
CDH5 hsa-miR-4254 3 7mer-m8 0,17
CDH5 hsa-miR-1914-3p 3 7mer-m8 0,1
CDH5 hsa-miR-3919 3 7mer-m8 0,05
a Evaluated as in [25].
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N-status, with ~6-fold higher risk of relapse for patients with nodal
involvement and tumors expressing high miR-939 levels compared
to patients without nodal involvement and tumors with low miR-
939 expression (Table 1 and Supplementary Fig. S1B). The Syn-
ergy index S evaluation [23] revealed that the interaction between
miR-939 and N status is synergistic: S ¼ 7.3 (95% CI ¼ 1.77e30.09).
miR-939 directly targets VE-cadherin
MDA-MB-231 BC cells induced to overexpress miR-939 did not
differ appreciably from non-induced cells with respect to prolifer-
ation, migration, or invasion ability (Supplementary Fig. S2). miR-
Walk analysis showed that miR-939 is predicted to target VE-
cadherin, a key regulator of endothelial adherens junctions
involved in the maintenance of contact between endothelial cells
and in vessel permeability control. In addition, miR-939 showed the
strongest Contextþþ score [25] among the eight miRNAs predicted
to bind VE-cadherin 30UTR by all prediction tools in miRWalk
(Table 2).
To test whether miR-939 might play an extracellular role in
disrupting endothelial junctions, HUVECs were transfected with
miR-939 or a scramble (scr) oligonucleotide for 48 and 72 h and VE-
cadherin modulation was assessed by Western blot and qRT-PCR.
miR-939 overexpression, veriﬁed by qRT-PCR (Fig. 2A), induced a
40e60% reduction of VE-cadherin protein expression levels (Fig. 2B
and C) but no signiﬁcant reduction in VE-cadherin mRNA expres-
sion (Fig. 2D). Decay of VE-cadherin mRNA was similar in HUVECs
transfected with miR-939, or scr, and treated with actinomycin D to
inhibit mRNA new transcription (Supplementary Fig. S3A-B). These
data indicate that miR-939 induces inhibition of mRNA translation
but not its degradation.
To verify the direct regulation of VE-cadherin by miR-939, the
30UTR of human CDH5, containing the three predicted miR-939
binding sites (Fig. 2E), was cloned into the reporter plasmid
pmiR-GLO vector and a luciferase assay was performed. Luciferase
activity in HEK-293 cells was reduced by 25% after miR-939 over-
expression (p¼ 0.019) compared to scr (Fig. 2F). A similar reduction
in luciferase activity was observed also in TNBCs cell lines
(Supplementary Fig. S3C). Themutation of individual or all miR-939
binding sites in the CDH5-30UTR prevented the down regulation of
luciferase activity (Fig. 2F), consistent with the contribution of each
miR-939 binding site to the downregulation of VE-cadherin
expression.
Down-modulation of VE-cadherin by miR-939 decreases monolayer
integrity of HUVECs
To further test the functional effect of miR-939 on endothelial
cells, HUVECs transfected with miR-939 mimic or scr
were analyzed by confocal microscopy for their ability to form a
stable endothelial monolayer. Consistent with the adhesive role ofTable 1
miR-939 interacts with lymph node status in disease-free survival of TNBC primary
tumors.
HRa 95% C.I. P-value
miR-939/N 1
miR-939þ/N 1.59 0.37e6.77 0.533
miR-939/Nþ 3.63 0.77e17.08 0.103
miR-939þ/Nþ 5.81 1.41e23.39 0.015
Multifocality, yes 4.25 1.28e14.18 0.018
Size, >2 cm 2.84 0.93e8.64 0.066
a Adjusted hazard ratios from a Cox multivariate model.VE-cadherin, the reduction of its expression in transfected HUVECs
occurred at the junctional level with a loss of cell-cell contact
(Fig. 3A). An in vitro assay to test whether the vascular damage
induced by miR-939 impairs the vessel permeability showed that
overexpression of miR-939 in these cells signiﬁcantly increased the
passage of rhodamine-labeled dextran probes (relative molecular
mass 70 KDa) through HUVEC monolayers growing on 0.4-mm ﬁl-
ters of a Boyden chamber compared to the negative control
(Fig. 3B), indicating that miR-939 regulation of VE-cadherin
expression impairs endothelial cell function.
Because VE-cadherin is known to be involved in the vasculo-
genesis of endothelial cells [26], the effect of miR-939 on vascular
damage was evaluated in a tube formation assay. miR-939 over-
expression for 72 h induced a clear inhibition of HUVECs vascular
structure formation (Fig. 3C), down-modulating VE-cadherin pro-
tein expression as shown by Western blotting (Fig. 3D).
miR-939 is transferred to endothelial cells via exosomes
HUVECs cultured for 16 h with exosomes puriﬁed from the su-
pernatant of MDA-MB-231 cells and labeled with PKH67 showed
uptake and internalization of the exosomes, visualized as green
vesicles in the cytoplasm (Supplementary Fig. S4A). Western blot
analysis revealed the exosomal marker CD63 only in exosome ly-
sates, while the cytoplasmic marker a-tubulin was present only in
MDA-MB-231 cell lysates (Supplementary Fig. S4B), conﬁrming
these vesicles as exosomes [27]. In exosomes puriﬁed from MDA-
MB-231 cells transfected for 48 h with mimic miRNA, levels of miR-
939 were 150e200 times higher than in those derived from cells
transfected with control (Fig. 4A). Treatment of HUVECs with exo-
somes containing miR-939 for 48 h induced an increase (4- to 5-
fold, p ¼ 0.093) of the cellular levels of mature miR-939
compared to levels in cells treated with control exosomes
(Fig. 4B). By contrast, pri-miR-939 expression levels were the same
in cells treated with miR-939 or control exosomes (Fig. 4C), indi-
cating that the increased miR-939 found in HUVECs reﬂects
exosome-mediated miRNA transfer and not induction of its
transcription.
Exosome-associated miR-939 increases tumor cell trans-endothelial
migration
Western blot analysis of VE-cadherin expression to assess con-
sequences of miR-939 transfer from tumor cells to the endothelial
monolayer revealed a 40% reduction of this protein in HUVECs at
48 h after treatment with miR-939-containing exosomes (Fig. 4D).
In addition, confocal microscopy to assess endothelial junction
integrity revealed a marked reduction of VE-cadherin and cell-cell
contacts in HUVECs treated with miR-939-containing exosomes
compared to controls (Fig. 4E). To further investigate the role of
miR-939 in tumor progression, we simulated the step of metastatic
Fig. 2. miR-939 directly targets VE-cadherin. A, miR-939 expression in HUVECs transfected with 100 nM miR-939 mimic (miR-939) or scramble (scr) oligonucleotide as evaluated
by qRT-PCR and normalized to RNU44. Data are shown as mean ± SD relative to the respective scr-transfected cells (set to 1), (n ¼ 2). ***P < 0.001 by unpaired Student's t-test. B,
representative Western blot of VE-cadherin in HUVECs transfected with miR-939 for 48 and 72 h. b-actin was used as protein loading control. C, Western blot quantiﬁcation relative
to VE-cadherin expression in scr-transfected cells. Data are mean ± SD (n ¼ 3). **P < 0.01 by paired Student's t-test. D, qRT-PCR quantitation of VE-cadherin in HUVECs transfected
with miR-939 for 48 and 72 h. Data are mean ± SD relative to the respective scr-transfected cells (48 h n ¼ 5, 72 h n ¼ 3). E, schematic representation of the interaction between
miR-939 and the binding sites in wild-type CDH5-30UTR. The 7-6 bp modiﬁed in the mutated forms (mut1-mut2-mut3) are in boldface. F, relative luciferase activity in HEK-293 cells
transfected with miR-939 and wild-type (wt) or mutated CDH5-30UTR. Data [mean ± SD (n ¼ 3)] are shown as luciferase activity relative to the value obtained in the respective scr-
transfected cells. *P < 0.05 by paired Student's t-test.
Fig. 3. miR-939 perturbs VE-cadherin activity in HUVECs. A, Confocal microscopy analysis of VE-cadherin (red) expression in HUVECs transfected with miR-939 or scr for 72 h.
Nuclei were counterstained with DAPI (blue). Scale bars: 50 mm. Arrows indicate loss of cellecell contact. Images are reported as extended depth-of-ﬁeld and are representative of 3
independent experiments. B, Monolayer permeability of HUVECs transfected with miR-939 or scr evaluated based on absorbance (590 nm) in the lower chamber of a Boyden
chamber with a HUVEC monolayer grown on a 0.4-mm ﬁlter. Data are mean ± SD (representative results of 2 experiments). *P < 0.05 by unpaired Student's t-test. C, Tube formation
ability of HUVECs transfected with miR-939 or scr as evaluated by phase-contrast light microscopy (4X) (NIKON TE Eclipse-S). Results are representative of 2 independent ex-
periments. D, Western blot of VE-cadherin in HUVECs at the time of tube formation assay. b-actin was used as protein loading control.
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well ﬁlter to form a monolayer and treating them with exosomes
containing miR-939; after 48 h, MDA-MB-231-GFP (231-GFP) cells
were seeded on the endothelial cells and left to migrate for 6 h.Analysis of trans-endothelial migration of cancer cells revealed a
signiﬁcant increase in the number of 231-GFP cells transmigrating
through the endothelial monolayer treated with miR-939-
containing exosomes compared to controls (Fig. 4F).
Fig. 4. miR-939 transfer increases trans-endothelial migration of TNBC cells by interfering with endothelial barrier integrity. A, Quantiﬁcation of miR-939 expression by qRT-PCR in
exosomes derived from MDA-MB-231 cells transfected with miR-939 or scr. miR-939 was normalized to the spike-in ath-miR-159a as reference. Data are mean ± SD (representative
results of 2 experiments). ***P < 0.001 by unpaired Student's t-test. B and C, miR-939 and pri-miR-939 expression, respectively, in HUVECs as evaluated by qRT-PCR 48 h after
treatment with exosomes. miR-939 and pri-miR-939 expression was normalized to RNU44 and GAPDH, respectively. Data are from 3 independent experiments. D, Representative
Western blot of VE-cadherin in HUVECs treated for 48 h with exosomes derived from transfected MDA-MB-231 cells. b-actin was used as protein loading control. Data were
quantiﬁed and expressed as relative amount (n ¼ 3). E, Confocal microscopy analysis of VE-cadherin (red) expression in HUVECs treated for 48 h with miR-939-containing exo-
somes. Nuclei were counterstained with DAPI (blue). Images, representative of 3 independent experiments, were acquired in a single plane. Scale bars: 50 mm. Arrows indicate loss
of cell-cell contact. F, Trans-endothelial migration of MDA-MB-231-GFP cells through HUVEC monolayers treated with miR-939-containing exosomes. MDA-MB-231-GFP was
quantiﬁed using Image-Pro Plus 7.0.1 software by measuring the green ﬂuorescence area on the bottom of the Transwell in each ﬁeld. At least 3 ﬁelds were randomly selected. Data
are mean ± SD (n ¼ 3). **P < 0.01 by paired Student's t-test.
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exosome-associated miR-939
To test whether TNBC cell exosomes contain miR-939, we pu-
riﬁed exosomes from supernatants of the TNBC cell lines MDA-MB-
231, MDA-MB-468 and SUM149. As shown in Fig. 5, miR-939 is
expressed both intracellularly (A) and in exosomes (B). To assess
the ability of TNBC cell exosomes to regulate VE-cadherin in
endothelial cells, HUVECs were treated for 24 h with 20 mg of pu-
riﬁed exosomes and, consistent with previous results, VE-cadherin
was down-regulated compared to untreated cells (Fig. 5C and
Supplementary Fig. S5A). To conﬁrm the direct involvement of miR-
939 in down-modulating VE-cadherin, a speciﬁc mercury LNA™-
miR-939-inhibitor (LNA939i) or a negative control (LNAneg) were
transfected in MDA-MB-231, MDA-MB-468 and SUM149 cells
(Supplementary Fig. S5B) and after 72 h, supernatants were
collected to purify exosomes. Western blot analysis revealed the
expected VE-cadherin reduction in HUVECs treated with exosomes
from cells transfected with LNAneg as compared to untreated
HUVECs (NT). Differently, HUVECs receiving LNA-939i-exosomes
from MDA-MB-231 and SUM149 showed an increased VE-
cadherin expression when compared to exo-LNAneg treated cells
but not when compared to NT (Fig. 5D and Supplementary
Fig. S5C). These data indicate that miR-939 is the main respon-
sible for VE-cadherin protein regulation in HUVECs.
Discussion
In this study, we ﬁnd that miR-939 is upregulated in human BCs,
particularly in the most aggressive basal-like subtypes. Analysis of
miR-939 expression in a cohort of 63 TNBC patients identiﬁed miR-
939 as a negative prognostic factor for DFS supporting its pro-tumorigenic properties in this highly aggressive subtype. Indeed,
lymph node-positive tumors overexpressing miR-939 have an
increased risk of relapse as compared with those with lower levels
of miR-939 and lacking lymph node involvement. These data sug-
gest that while miR-939 alone is not sufﬁcient to induce metasta-
ses, its activity contributes to the metastatic process in tumor cells
able to disseminate to lymph nodes.
Unlike ovarian cancer cells [17], overexpression of miR-939 in
MDA-MB-231 cells did not increase their proliferation and migra-
tion ability. Instead, proliferationwas slightly decreased, consistent
with the reported association of this miRNA to apoptosis [28]. Even
though we cannot exclude a prometastatic effect of intracellular
miR-939 in TNBC, our in silico analysis identifying VE-cadherin as a
miR-939 target and our in vitro data support its role in cancer
progression through the modulation of the surrounding microen-
vironment. Despite the association of miR-939 prognostic impact
with its ability to increase intra-/extravasation awaits quantitation
of circulating miR-939 in BC patients, an extracellular role for miR-
939 is consistent with its presence in the blood of patients with
lung [15] and hepatocarcinomas [16] and in patients with chronic
neuropathic disorders [29].
Further, our ﬁnding that miR-939 overexpression in endothelial
cells led to decreased VE-cadherin protein but not mRNA expres-
sion indicates that the mechanism exploited by miR-939 for target
regulation is the inhibition of mRNA translation instead of mRNA
degradation.
In addition to the validation of VE-cadherin as a miR-939 target
by luciferase assay, our confocal microscopy analysis showed that
disruption of VE-cadherin induces loss of contact between cells,
consistent with the decreased ability of HUVECs to form tubules
upon loss of VE-cadherin [30]. Tumor cells disseminating in the
organism may exploit the impairment of the adherens junctions to
Fig. 5. miR-939 is expressed and released in exosomes of TNBC cell lines and its uptake in HUVECs downmodulates VE-cadherin. A and B, Intracellular and exosomal miR-939
expression levels, in MDA-MB-231, MDA-MB-468 and SUM149 cells as evaluated by qRT-PCR. U44 and miR-21 were respectively used for miR-939 normalization. Data are
mean ± SD (n ¼ 2). C and D, Western blot of VE-cadherin in HUVECs treated or not (NT) for 24 h with exosomes derived from BC cell wild-type (C) and from cells transfected with
LNA-939 inhibitor (D). b-actin was used as protein loading control. Results are representative of 3 experiments.
M. Di Modica et al. / Cancer Letters 384 (2017) 94e100 99enter into the vessels and spread to secondary sites. Our results
suggest that miR-939 secretion is sufﬁcient to open “gates” in tu-
mor blood vessels for the traversal of cancer cells favoring hema-
togenous tumor spread. In early-stage metastatic BC, tumor cells
disseminate through both lymphatic and hematogenous systems,
although the factors determining the route remain unknown [31].
Since TNBC patients are characterized by capillary invasion more
than lymphatic invasion [32], miR-939 expression could be of
particular importance for tumor cells to acquire the capacity to
metastasize to distant sites. However, the evidence that VE-
cadherin is also present in lymphatic vessels, particularly in ter-
minal lymphatic endothelial cells [33], raises the possibility that
tumor cells exploit this mechanism to enter also lymphatic vessels.
Consistently, cancer-secreted miRNAs are increasingly recog-
nized as mediators of cancer-endothelial cell crosstalk: tumor-
derived exosome-mediated transfer of miR-105 to endothelial
monolayers efﬁciently destroys tight junctions and the integrity of
this natural barrier against metastasis [4]. Although it remains
unclear whether miRNAs exist in the systemic circulation pre-
dominantly free, associated to proteins [34], or are transported via
tumor-secreted microvesicles such as exosomes [35], there is evi-
dence that exosome-associated miRNAs are more stable and thus
more functional in modulating microenvironmental cell functions
[36]. Indeed Zhou et al. [4] showed that onlymiRNAs internalized in
exosomes can be up taken by recipient cells to exert their function.
For this reason we only focused on miR-939-associated exosomes,
even though miR-939 is reported equally distributed in exosomes
and in serum [16]. The miR-939 sequence contains the loading
motif recognized by the heterogeneous nuclear ribonucleoprotein
A2B1 (hnRNAB1) [37], indicating that it is actively loaded into
exosomes. Thus, it is possible that tumor cells purposely release
miR-939 into exosomes to modulate VE-cadherin expression in
order to locally and transiently disrupt the barrier function of
endothelial cells that normally express lowmiR-939 levels. Indeed,
tumor-derived exosome-mediated transfer of miR-939 caused a
reduction in VE-cadherin expression in the endothelial cell creating
gap in the endothelial monolayer, as observed by transfecting miR-
939 in HUVECs. Furthermore, miR-939 transfer into endothelial
cells led to an increase in TNBC cells trans-endothelial migration
due to the weakening of the endothelial barrier, as demonstrated inour trans-endothelial migration assay. Since monolayer integrity is
maintained by adherens junctions through VE-cadherin but also by
tight junctions that contain ZO-1, which is reportedly down-
regulated via BC exosomes [4], we performed these experiments
with exosomes from MDA-MB-231 cells transfected with miR-939
mimic in order to focus speciﬁcally on the effects caused by this
miRNA.
Analysis of TNBC cell lines showed that these cells endogenously
express and release sufﬁcient miR-939 in exosomes to down-
modulate VE-cadherin when taken up in HUVECs. Furthermore,
the blockade of miR-939 with speciﬁc miRNA-LNA inhibitor in
exosome-releasing MDA-MB-231 and SUM149 cells did not down-
modulate VE-cadherin in HUVECs compared to controls. Thus, the
regulation of VE-cadherin can be ascribed to miR-939 in TNBC cells
that release high amount of this miRNA.
Together, our data demonstrate an association between miR-
939 expression and worse prognosis in TNBC, likely due to its
role in the extracellular milieu, where it increases cell trans-
migration through the endothelial barrier by disrupting contact
between endothelial cells.Funding
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